Sandoz

News

Sanofi's RA drug Kevzara approved in Europe

Sanofi’s next-generation rheumatoid arthritis drug Kevzara has been approved in Europe, giving a new option for patients who are intolerant to other treatments.

News

Sandoz weighs into European rituximab biosimilar market

Sandoz has gained European approval for its biosimilar version of Roche's blockbuster MabThera/Rituxan (rituximab) to be called Rixathon.

News

Sandoz files Humira and Remicade biosimilars in EU

European regulators to review Sandoz’s Humira and Remicade biosimilars.

News

Sandoz buys into Durect's long-acting painkiller

Sandoz has signed a potential $293 million agreement to develop and market Durect’s Posimir, an extended-release, locally-acting, non-opioid painkiller in the US.

Views & Analysis